Articles On Dimerix (ASX:DXB)

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

Shareholders of Dimerix (ASX:DXB) got an early Christmas present with the company telling them its Phase 3 clinical trial testing its DMX-200 drug against COVID-19 pneumonia respiratory complications in Europe was on track. The study (REMAP...

The REMAP-CAP Data Safety Monitoring Board (DSMB) has recommended Dimerix (DXB) continues enrolments for its ACE2 renin angiotensin system (RAS) modulation study Dimerix has so far recruited 662 COVID-19 pneumonia patients in Europe with 4...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

We invested in Dimerix (ASX:DXB) in August for its fully funded Phase III clinical trials treating FSGS (a rare kidney disease) and its two near term Phase III trials for COVID-19. In early stage biotech investing, Phase III trials are the...

Dimerix (DXB) is granted Australian ethics and regulatory approval for its Phase 3 clinical trial in FSGS kidney patients The clinical trial will see the company evaluate the efficacy and safety of DMX-200 against a placebo in patients wit...

Dimerix is partnering with the NHMRC Clinical Trials Centre at the University of Sydney to expand a feasibility/phase 3 trial of its DMX-200 drug candidate to treat COVID-19 sufferers with respiratory complications.

The Dimerix Ltd (ASX: DXB) share price is gaining more field position in afternoon trade and is now changing hands at 28.5 cents. That’s an approximate 4% gain for the biopharmaceutical company today after it released a key update regardi...

Regular Finfeed readers should be familiar by now with Dimerix (ASX:DXB) - the first investment in our small cap ASX listed biotech portfolio. DXB has developed a treatment for inflammatory diseases, such as kidney and respiratory diseases....

Dimerix (DXB) enters an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.0 clinical study The study, which is already approved and recruiting in India, will recruit 600 patients across Ind...

Cronos Australia (ASX:CAU) jumped 7% this morning, after reporting significant growth in the sales of its Adaya medicinal cannabis range — up 90% from the previous quarter. Sales of Adaya for the first quarter have exceeded $1.1m, Cronos sa...

Today we announce the fourth addition to our portfolio for 2021. Today we are adding Dimerix (ASX:DXB) to the Next Investors portfolio as our inaugural Biotech Pick of the Year for 2021.

The capital structure for DXB’s marquee capital raise was signed off by shareholders at its AGM last month. ASX biotech Dimerix (ASX:DXB) closed out a big month on equity capital markets with an oversubscribed share purchase plan (SPP) last...

Clinical-stage drug development company Dimerix (ASX:DXB) has announced that the Indian regulator has formally recommended the approval of the study of DMX-200 in patients with COVID-19.

The Dimerix Ltd (ASX: DXB) share price is taking off today. Meanwhile, the company has conducted its annual general meeting (AGM). At the meeting, CEO Dr Nina Webster looked back on a year she described as “pivotal for the future of Dimeri...

Dimerix’s lead drug candidate DMX-200 has been given regulatory green light for approval for a Phase 3 study in COVID-19 ravaged India. Clinical-stage biotech Dimerix (ASX:DXB)  has received approval from the review committee in India for...

Our new business model is to research, analyse, and invest in up and coming small cap ASX-listed biotech stocks that we believe have a high chance of success. We then share our research and commentary along our investment journey with our r...

The broad Australian indices have started the day off in the red as the market resets from a number of stirrups this week. The S&P/ASX 200 index (ASX: XJO) has clipped 0.37% lower today and sits at 7,343 points, whereas the S&P/AS...

Shares in Dimerix Ltd (ASX: DXB) are soaring today, shooting up 9% in early trade. At the time of writing, the Dimerix share price has retreated slightly and is now trading at 30 cents apiece, up 7.4%. Below we take a look at the clinical-...

The ASX 200 health stocks index (XHJ) is down by 0.82% at the time of writing, compared to the broader ASX 200 index which is down by 0.08% Respiratory tech specialist, Adherium (ASX:ADR), jumped 12% this morning after saying it was awarded...

The placement gives Dimerix a flexible, long-term funding solution as the Phase 3 clinical trial kicks off with first ethics submission. For biopharmaceutical companies, securing new funding pathways for the development of complex clinical...

August was another month of lockdown for much of Australia’s East Coast but lockdowns and even a 2% drop in the middle of the month couldn’t stop the ASX from producing another winners list. The ASX 200 ultimately finished August 1.9% highe...

The Dimerix Ltd (ASX: DXB) share price is gaining today despite no news having been released by the company. In fact, the market hasn’t heard anything from Dimerix in more than a week. Right now, Dimerix’s shares are swapping hands for 35...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

Clinical-stage biopharmaceutical company Dimerix (ASX: DXB) has commenced the phase three ACTION3 clinical study in patients with focal segmental glomerulosclerosis.

Dimerix has hit a major milestone in its bid to provide an effective treatment for patients with a rare kidney disease. Clinical stage biopharmaceutical company Dimerix (ASX:DXB) has announced it has started the Phase 3 clinical study of i...

The ASX 200 health stocks index (XHJ) rose by 0.60% this morning, compared to the broader index which climbed by 0.40% Biopharmaceutical company Dimerix (ASX:DXB) announced that it has commenced ACTION3, a Phase III study in patients with f...

It was another positive close for the Australian bourse today with energy the standout sector. The ASX 200 closed 0.17% higher at 7,503 points while the ASX Emerging Companies Index gained 1.1% to close at 2,262 points. Leading the charge w...

The Dimerix Ltd (ASX: DXB) share price has sunk well into the red from the opening of trade on Tuesday. Dimerix shares are on the way down as the company advised it had lodged a prospectus with the Australian Securities and Investment Com...

Ikwezi Mining (ASX:IKW) topped the latest Running Hot list with a 14-day RSI of 82, after two straight weeks where lithium stocks dominated. Each week, Stockhead recaps ASX stocks that are “running hot” as deduced by the Relative Strength I...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

Highlights The trend of buying meme stocks in order to make a quick windfall profit has spread to the Australian markets as well. Archer Materials, despite zero sales in FY21, has rallied over 310% since 24 June 2021 on the back of a m...

Clinical-stage biopharmaceutical company Dimerix (ASX:DXB) has announced a $20 million capital raise via a two-tranche placement of approximately 100 million new shares.

The S&P ASX200 closed lower Monday, dropping 46.40 points or 0.61% to 7,582.50 after setting a new 52-week high. The bottom performing stocks in this index were Beach Energy Limited (ASX:BPT) and Bendigo and Adelaide Bank Limited (ASX:B...

Highlights Seven West Media’s EBITDA more than doubled to AU$253.9 million during FY21. JBH Hi-Fi’s sales were up 12.6% to AU$8.9 billion in FY21 as heightened customer demand for consumer electronics continued. Sydney Airport has rej...

Today we announce the fourth addition to our portfolio for 2021. Today we are adding Dimerex (ASX:DXB) to the Next Investors portfolio as our inaugural Biotech Pick of the Year for 2021.

The Dimerix Ltd (ASX: DXB) share price is skyrocketing in late morning trade, up 50% to 35 cents per share. This comes as the biopharmaceutical company emerges from Thursday’s trading halt, announcing a successful capital raising and relea...

Merchant Group’s new biotech fund has made its first investment, backing Dimerix alongside former Worley Parsons executive Peter Meurs.

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

Dimerix (ASX:DXB) has announced that 167 patients have now been recruited into the feasibility/Phase 3 ACE2 renin-angiotensin system modulation study domain in patients with COVID-19 pneumonia that incorporates DMX-200.

Patient recruitment and the number of clinical sites for the European COVID-19 treatment study involving Dimerix’s CCR2-inhibitor DMX-200 has increased, and preliminary results expected by the end of 2021. Biopharmaceutical company Dimerix...

Biopharmaceutical company Dimerix (ASX:DXB) makes significant operational advances in the quarter with global support of regulators. Biopharmaceutical company Dimerix (ASX:DXB)  has closed out the June quarter with key support from global r...

Wall Street rises ahead of Fed Reserve decision All three major US benchmarks rose modestly on Monday to reach new records, as the market awaits the result of US Fed’s two-day meeting currently underway. The Dow Jones and S&P 500 were u...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

Support from the FDA gives DBX additional clarity as it builds out globally significant Phase 3 trials in the second half of this year. Biopharmaceutical company Dimerix (ASX:DXB) continues to attract the support of global regulators, as it...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week It has been...